The initial success of the copyright undeniably transformed the pharmaceutical landscape, but investing in companies strongly reliant on unbranded versions presents a challenging picture. While early earnings were impressive, the read more expiration of patents and the rise of less expensive alternatives have weakened the customer base. Thus, a tho